Anti-JAK2/ JAK-2/ JTK10 monoclonal antibody

Anti-JAK2/ JAK-2/ JTK10 antibody for FACS & in-vivo assay

Target products collectionGo to JAK-2/JAK2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T08391-Ab-1/ GM-Tg-hg-T08391-Ab-2Anti-Human JAK-2/JAK2 monoclonal antibodyHuman
GM-Tg-rg-T08391-Ab-1/ GM-Tg-rg-T08391-Ab-2Anti-Rat JAK-2/JAK2 monoclonal antibodyRat
GM-Tg-mg-T08391-Ab-1/ GM-Tg-mg-T08391-Ab-2Anti-Mouse JAK-2/JAK2 monoclonal antibodyMouse
GM-Tg-cynog-T08391-Ab-1/ GM-Tg-cynog-T08391-Ab-2Anti-Cynomolgus/ Rhesus macaque JAK-2/JAK2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T08391-Ab-1/ GM-Tg-felg-T08391-Ab-2Anti-Feline JAK-2/JAK2 monoclonal antibodyFeline
GM-Tg-cang-T08391-Ab-1/ GM-Tg-cang-T08391-Ab-2Anti-Canine JAK-2/JAK2 monoclonal antibodyCanine
GM-Tg-bovg-T08391-Ab-1/ GM-Tg-bovg-T08391-Ab-2Anti-Bovine JAK-2/JAK2 monoclonal antibodyBovine
GM-Tg-equg-T08391-Ab-1/ GM-Tg-equg-T08391-Ab-2Anti-Equine JAK-2/JAK2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T08391-Ab-1/ GM-Tg-hg-T08391-Ab-2; GM-Tg-rg-T08391-Ab-1/ GM-Tg-rg-T08391-Ab-2;
GM-Tg-mg-T08391-Ab-1/ GM-Tg-mg-T08391-Ab-2; GM-Tg-cynog-T08391-Ab-1/ GM-Tg-cynog-T08391-Ab-2;
GM-Tg-felg-T08391-Ab-1/ GM-Tg-felg-T08391-Ab-2; GM-Tg-cang-T08391-Ab-1/ GM-Tg-cang-T08391-Ab-2;
GM-Tg-bovg-T08391-Ab-1/ GM-Tg-bovg-T08391-Ab-2; GM-Tg-equg-T08391-Ab-1/ GM-Tg-equg-T08391-Ab-2
Products NameAnti-JAK-2/JAK2 monoclonal antibody
Formatmab
Target NameJAK-2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-JAK-2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species JAK2/ JAK-2/ JTK10 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLPm003630mouse Jak2 Lentivirus plasmid
    ORF Viral VectorvGMLPm003630mouse Jak2 Lentivirus particle


    Target information

    Target IDGM-T08391
    Target NameJAK-2
    Gene ID3717,16452,24514,694184,484185,101088959,525246,100051487
    Gene Symbol and SynonymsFd17,JAK2,JTK10
    Uniprot AccessionO60674,Q62689
    Uniprot Entry NameJAK2_HUMAN,JAK2_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseCancer
    Gene EnsemblENSG00000096968
    Target ClassificationKinase, Tumor-associated antigen (TAA)

    The target: JAK-2, gene name: JAK2, also named as JTK10, THCYT3. This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.